Evaluating Nulojix Long-Term Safety in Transplant.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 15 May 2017
At a glance
- Drugs Belatacept (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions
- Acronyms ENLiST
- Sponsors Bristol-Myers Squibb
- 09 May 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Feb 2016 Planned number of patients changed from 3500 to 1130, according to ClinicalTrials.gov record.
- 12 Feb 2016 Planned End Date changed from 1 Jan 2017 to 1 Apr 2019, according to ClinicalTrials.gov record.